Avalo Therapeutics, Inc. (AVTX) Total Assets by Year
Avalo Therapeutics, Inc. closed fiscal year 2025 with $116.5M in total assets, $33.4M in total liabilities and $83.0M in shareholder equity. This represents a decrease of 22.7% from the prior fiscal year. The table below carries 13 fiscal years, from 2013 to 2025, and the quarters Avalo Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
AVTX Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $116.5M-22.7% | $150.7M+618.0% | $21.0M-37.1% | $33.4M-58.4% | $80.2M+83.3% | $43.8M+21.2% | $36.1M-48.6% | $70.3M+64.1% | $42.8M+642.0% | $5.8M-73.4% | $21.7M+75.8% | $12.3M | N/A |
| Total Liabilities | $33.4M+88.8% | $17.7M+29.3% | $13.7M-69.1% | $44.3M-22.5% | $57.1M+197.7% | $19.2M+27.0% | $15.1M-69.4% | $49.3M+230.1% | $14.9M+168.7% | $5.6M-35.1% | $8.6M-77.8% | $38.6M | N/A |
| Total Equity | $83.0M-37.6% | $133.0M+1721.4% | $7.3M+166.9% | -$10.9M-147.3% | $23.1M-6.0% | $24.6M+17.0% | $21.0M+0.4% | $20.9M-25.0% | $27.9M+13358.6% | $207K-98.4% | $13.1M+149.7% | -$26.3M-47.5% | -$17.8M |
AVTX Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $490.8M+287.7% | $99.9M-27.9% | $116.5M-22.7% | $125.1M+27.1% | $126.6M+16.9% | $138.5M+12.0% | $150.7M+618.0% | $98.5M+236.4% | $108.3M+346.9% | $123.7M+241.5% | $21.0M-37.1% | $29.3M-19.9% |
| Total Liabilities | $42.1M+91.4% | $31.6M+98.4% | $33.4M+88.8% | $33.6M-55.7% | $22.0M-80.1% | $15.9M-92.9% | $17.7M+29.3% | $75.7M+419.5% | $110.5M+254.0% | $224.8M+428.9% | $13.7M-69.1% | $14.6M-62.2% |
| Total Equity | $448.7M+329.0% | $68.3M-44.3% | $83.0M-37.6% | $91.5M+334.4% | $104.6M+868.5% | $122.6M+209.0% | $133.0M+1721.4% | $21.1M+43.4% | -$13.6M-95.3% | -$112.5M-1695.8% | $7.3M+166.9% | $14.7M+824.6% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Avalo Therapeutics, Inc. financials
Frequently Asked Questions
What was Avalo Therapeutics, Inc.'s total assets in fiscal year 2025?
Avalo Therapeutics, Inc. closed fiscal year 2025 with $116.5M in total assets, $33.4M in total liabilities and $83.0M in shareholder equity.
How fast is Avalo Therapeutics, Inc.'s total assets growing?
Avalo Therapeutics, Inc. (AVTX) total assets fell by 22.7% year over year, from $150.7M to $116.5M in fiscal year 2025.
What was Avalo Therapeutics, Inc.'s total assets in the most recent quarter?
Avalo Therapeutics, Inc. (AVTX) reported $490.8M in total assets in Q2 2026. This represents an increase of 287.7% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Avalo Therapeutics, Inc. (AVTX) reported on that line in every period on record.